Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Search Site

Over 2,750 Pages of
Hepatitis C Info, Here:
Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

UK needs more hepatitis awareness
Britons need to be educated on the dangers of hepatitis B and C, the British Liver Trust has claimed. According to the organization, the conditions have a low public profile - something which means people are not very concerned about catching them.

Bristol-Myers Squibb Welcomes NICE Guidance Recommending Baraclude(R) (entecavir) as a Treatment Option for Chronic Hepatitis B
UXBRIDGE, England, August 29 (HSMN NewsFeed) -- NICE (National Institute for Health and Clinical Excellence) has published guidance that recommends Baraclude (entecavir) as an option for treatment of eligible patients with chronic hepatitis B (CHB).

China's Hepatitis B Virus Drug Market Will Grow to $800 Million by 2012
Competition From Chinese Makers Present Considerable Challenge to Branded Western Drug Companies Seeking to Penetrate Market, According to a New Report From Decision Resources WALTHAM, Mass., August 28, 2008 /PRNewswire/ -- Decision Resources, one of the

UPDATES AND COMMENTARY RSS Feed

Hep C Treatment: Comparing the Pegylated Interferons
Learn about the facts on pegylated interferon alfa-2a and pegylated interferon alfa-2b, the standard treatment for chronic Hepatitis C. Comparing and contrasting the pegylated interferons may help better explain a physician’s preference or indifference between the two when treating their...

Vertex's Advanced Trial Could Change HCV Treatment
Hundreds of non-responders to interferon-ribavirin combination therapy will be enrolled in a late stage clinical trial for Vertex's telaprevir....

Silymarin Improves Quality of Life During Hepatitis C Treatment
Although a large-scale study concluded long-term interferon therapy to be ineffectual for Hepatitis C management, it demonstrated improvements in quality of life for participants supplementing with silymarin....
Slow Progression Rate of Fibrosis in Hepatitis C Virus Patients With Persistently Normal Alanine Transaminase Activity

table  1.   Clinical and Biochemical Features
Patients With Normal ALT Patients With Elevated ALT
No. of patients 102 102
Age (mean ± SD range) 43.0 ± 13.8 (16-75) 44.0 ± 13.5 (24-74)
Median 40.5 (95% CI: 36-43) 39.0 (95% CI: 37-43)
Age at infection (mean ± SD range) 28.2 ± 13.9 (0-64) 28.9 ± 13 (6-64)
Median 24.0 (95% CI: 21-26) 24.0 (95% CI: 22-26)
No. of males/females 41/61 41/61
Ethnic origin
  Northern Europe 73% 78%
  Mediterranean 10% 12%
  Asia  6%  6%
  Africa 11%  4%
Alcohol consumption (g/d), mean ± SD range 16 ± 44 (0-240) 13 ± 40 (0-200)
Duration of infection (yr), mean ± SD range 14.9 ± 7.6 (3-41) 14.1 ± 7.1 (3-36)
Median 14.0 (95% CI: 12-15) 13.0 (10-15)
Drug abusers (%) 32% 31%
Transfusion (%) 35% 40%
Number of ALT dosages, mean ± SD (range) 6.3 ± 3.1 (3-15) 5.5 ± 2.5 (1-20)
ALT (IU/L), mean ± SD (range)§ 24.5 ± 8.9 (7-45) 140 ± 100 (50-494)*
Median 24 (95% CI: 22-25) 112 (95% CI: 97-124)
GGT (IU/L), mean ± SD (range) 26.4 ± 20.5 (5-112) 79.1 ± 96 (7-434)dagger
Median 20 (95% CI: 16-22) 45 (95% CI: 35-50)
Prothrombin time (% of normal), mean ± SD (range) 96 ± 8.8 (55-100) 95 ± 11 (18-100)
Serum bilirubin (µmol/L), mean ± SD (range) 11.8 ± 6 (3-38) 8.4 ± 2 (5-13)
Cryoglobulinemia 14% 37%Dagger
Cholesterol (mmol/L), mean ± SD (range) 5.2 ± 1.3 (2.8-7.9) 4.7 ± 1.1 (1.4-7.8)
Triglyceride (mmol/L), mean ± SD (range) 1.2 ± 0.6 (0.3-2.2) 1 ± 0.4 (0.4-2.4)
* P < .0001.
 dagger P < .0001.
 Dagger P < .02.
§ Upper limit of normal value was 45 IU/L.

Return To Article

table Of Contents

Copyright © 1998 by the American Association for the Study of Liver Diseases.
  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 30 Aug 2008